ATNM · Actinium Pharmaceuticals, Inc.
Market Cap
$43.70M
Shares
31.44M
Volume · Oct 20
801.42K
Avg daily vol (3M)
151.84K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.32
Open$1.14
Day$1.13–1.40
52W close$0.75–1.69
Avg vol 30d166K
Short int706K · 2.2% float · 8.7d
Short vol43%
DataJan 2020–Oct 2026
Filing10-Q · Aug 7
Up next
filed Aug 7, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
$11.31M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-40,274.4%
Trailing 12 months
P / E (TTM)
3.8
Trailing earnings · reciprocal yield 26.5%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$36.47M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.7%
Year over year · more shares
Price change (1Y)
-9.6%
Trailing year
Short interest
2.2%
Latest settlement · 8.7 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+18%
above
Price vs 50-day avg
+19%
above
RSI (14)
65
neutral
MACD trend
Positive
52-week position
61%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+10%
trailing
6-month return
+11%
trailing
YTD return
−3%
this year
Relative strength
+3%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
3 of 48 funds reported for Sep 30 · net -2.8K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.24% of float · ▼ -0.3% MoM · 8.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
48 holders — near 3-yr low, contrarian setup
Squeeze score
73
high risk · 0–100
Fundamentals
Revenue growth
+11%
Y/Y
Gross margin
0%
EPS growth
+14%
Y/Y
Free cash flow
$-24.7M
Valuation
P/E 4
in line
Balance sheet
$13.7M
net cash
Quant / Vol
risk profile
Volatility
72%
annualized · 1-yr
Max drawdown
−56%
past year
ATR
6.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+18%
Bullish
Price vs 50-day avg
+19%
Bullish
RSI (14)
65
Neutral
MACD trend
Positive
Bullish
52-week position
61%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
3 of 48 funds reported for Sep 30 · net -2.8K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.24% of float · ▼ -0.3% MoM · 8.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
48 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $1 · 61%
Range high $2
vs 200-day avg +18%
vs 50-day avg +19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATNM
this stock
Actinium Pharmaceuticals, Inc.
|
$43.70M | -2.9% | — | 4.0 | 2.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +10.7% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +1.3% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
SEC Filings
Latest
ARS
- Filed
- Oct 16, 2026
- This year
- 11
Actinium Pharmaceuticals' 2025 Annual Report describes it as a clinical-stage biopharmaceutical company developing targeted radiotherapies for solid tumors and hematologic malignancies, highlighting lead candidate ATNM-400's pre-clinical activity across mCRPC, NSCLC, and breast cancer.
ViewEarnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATNM | +24.5% | +10.0% | +10.9% | +17.9% | -2.9% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | +26.0% | +10.9% | +3.2% | +17.4% | -15.3% |